No Data
No Data
Johnson & Johnson reports Q2 2024 results
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
J&J Ends Work on Addex Epilepsy Drug Candidate ADX71149: Report
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.
Johnson & Johnson Shares Trade at Fair Value After Q2 Results, 2024 Guidance, Morgan Stanley Says
Johnson & Johnson's (JNJ) shares are trading at fair value based on a sum-of-the-parts analysis after Q2 results and 2024 revenue guidance was mostly in line with expectations, Morgan Stanley said
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The
Express News | TD Cowen Maintains Buy on Johnson & Johnson, Lowers Price Target to $185